155 related articles for article (PubMed ID: 18221052)
1. Inhibitors of steroidal cytochrome p450 enzymes as targets for drug development.
Baston E; Leroux FR
Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):31-58. PubMed ID: 18221052
[TBL] [Abstract][Full Text] [Related]
2. P450-dependent enzymes as targets for prostate cancer therapy.
De Coster R; Wouters W; Bruynseels J
J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):133-43. PubMed ID: 8603034
[TBL] [Abstract][Full Text] [Related]
3. 17alpha-hydroxylase/17,20-lyase (p450(17alpha)) inhibitors in the treatment of prostate cancer: a review.
Owen CP
Anticancer Agents Med Chem; 2009 Jul; 9(6):613-26. PubMed ID: 19601745
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of CYP 17, a new strategy for the treatment of prostate cancer.
Hartmann RW; Ehmer PB; Haidar S; Hector M; Jose J; Klein CD; Seidel SB; Sergejew TF; Wachall BG; Wächter GA; Zhuang Y
Arch Pharm (Weinheim); 2002 Apr; 335(4):119-28. PubMed ID: 12112031
[TBL] [Abstract][Full Text] [Related]
5. Novel functionalized 5-(phenoxymethyl)-1,3-dioxane analogs exhibiting cytochrome P450 inhibition: a patent evaluation WO2015048311 (A1).
Schroeder RL; Tram P; Liu J; Foroozesh M; Sridhar J
Expert Opin Ther Pat; 2016; 26(1):139-47. PubMed ID: 26514241
[TBL] [Abstract][Full Text] [Related]
6. [Advances in the study of steroidal inhibitors of cytochrome P45017alpha].
Du JJ; Chen HL; Li YC
Yao Xue Xue Bao; 2013 Jan; 48(1):25-31. PubMed ID: 23600137
[TBL] [Abstract][Full Text] [Related]
7. Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer.
Hu Q; Yin L; Hartmann RW
J Med Chem; 2012 Aug; 55(16):7080-9. PubMed ID: 22861193
[TBL] [Abstract][Full Text] [Related]
8. The adrenocortical tumor cell line NCI-H295R as an in vitro screening system for the evaluation of CYP11B2 (aldosterone synthase) and CYP11B1 (steroid-11beta-hydroxylase) inhibitors.
Müller-Vieira U; Angotti M; Hartmann RW
J Steroid Biochem Mol Biol; 2005 Aug; 96(3-4):259-70. PubMed ID: 15985365
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of 17alpha-hydroxylase/17,20-lyase (CYP17): potential agents for the treatment of prostate cancer.
Njar VC; Brodie AM
Curr Pharm Des; 1999 Mar; 5(3):163-80. PubMed ID: 10066888
[TBL] [Abstract][Full Text] [Related]
10. N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2).
Zimmer C; Hafner M; Zender M; Ammann D; Hartmann RW; Vock CA
Bioorg Med Chem Lett; 2011 Jan; 21(1):186-90. PubMed ID: 21129965
[TBL] [Abstract][Full Text] [Related]
11. Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo.
Haidar S; Ehmer PB; Barassin S; Batzl-Hartmann C; Hartmann RW
J Steroid Biochem Mol Biol; 2003 Apr; 84(5):555-62. PubMed ID: 12767280
[TBL] [Abstract][Full Text] [Related]
12. Enzyme-activated inhibitors of steroidal hydroxylases.
Johnston JO; Wright CL; Holbert GW
J Steroid Biochem Mol Biol; 1995 Jan; 52(1):17-34. PubMed ID: 7857870
[TBL] [Abstract][Full Text] [Related]
13. Stepwise binding of inhibitors to human cytochrome P450 17A1 and rapid kinetics of inhibition of androgen biosynthesis.
Guengerich FP; McCarty KD; Chapman JG; Tateishi Y
J Biol Chem; 2021 Aug; 297(2):100969. PubMed ID: 34273352
[TBL] [Abstract][Full Text] [Related]
14. Environmental inhibitors of the expression of cytochrome P450 17A1 in mammals.
Peng Z; Xueb G; Chen W; Xia S
Environ Toxicol Pharmacol; 2019 Jul; 69():16-25. PubMed ID: 30921671
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of p450 17 as a new strategy for the treatment of prostate cancer.
Leroux F
Curr Med Chem; 2005; 12(14):1623-9. PubMed ID: 16022662
[TBL] [Abstract][Full Text] [Related]
16. Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls.
Hille UE; Hu Q; Vock C; Negri M; Bartels M; Müller-Vieira U; Lauterbach T; Hartmann RW
Eur J Med Chem; 2009 Jul; 44(7):2765-75. PubMed ID: 19211174
[TBL] [Abstract][Full Text] [Related]
17. CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets.
Hakki T; Bernhardt R
Pharmacol Ther; 2006 Jul; 111(1):27-52. PubMed ID: 16426683
[TBL] [Abstract][Full Text] [Related]
18. Modulation of cytochromes P450 with xanthone-based molecules: from aromatase to aldosterone synthase and steroid 11β-hydroxylase inhibition.
Gobbi S; Hu Q; Negri M; Zimmer C; Belluti F; Rampa A; Hartmann RW; Bisi A
J Med Chem; 2013 Feb; 56(4):1723-9. PubMed ID: 23363058
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of novel steroidal oxime inhibitors of P450 17 (17 alpha-hydroxylase/C17-20-lyase) and 5 alpha-reductase types 1 and 2.
Hartmann RW; Hector M; Haidar S; Ehmer PB; Reichert W; Jose J
J Med Chem; 2000 Nov; 43(22):4266-77. PubMed ID: 11063622
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the potential of polyphenols as a CYP17 inhibitor free of adverse corticosteroid elevation.
Lin CJ; Cheng LC; Lin TC; Wang CJ; Li LA
Biochem Pharmacol; 2014 Aug; 90(3):288-96. PubMed ID: 24875446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
